Objectives: The site of action of efavirenz is inside HIV-infected cells. Measurement of intracellular (IC) concentrations of efavirenz may therefore provide further understanding of therapeutic failure, especially where virological rebound occurs despite adequate plasma levels, and a lack of detectable viral resistance. Here, we determined IC and plasma pharmacokinetics of efavirenz and their relationship with plasma protein binding and P-glycoprotein (P-gp, an active drug efflux transporter) expression.
Introduction
Despite the success of highly active antiretroviral therapy in reducing morbidity and mortality amongst HIV-infected patients, 1 therapeutic failure remains common. Although low plasma levels of efavirenz (<1000 ng/mL) have been linked to treatment failure, 2 measurement of intracellular (IC) efavirenz concentrations may give a better indication of antiviral exposure at the site of action.
To date, there is only one study describing the IC accumulation of efavirenz. 3 Rotger et al. 3 used Bayesian calculations to predict plasma and IC AUCs from single randomly timed samples and related these to CYP2B6 genotype and CNS toxicity. IC (or more accurately cell-associated) concentrations of other antiretrovirals have also been determined [4] [5] [6] [7] [8] [9] [10] and are thought to be the net result of a number of variables, such as the physiochemical properties of the drug, protein binding (plasma and IC) and active transport by influx and/or efflux proteins. As it is the unbound drug that is able to enter cells by passive diffusion, changes in the free fraction of efavirenz in plasma may alter its IC concentration. However, there are no data describing the free fraction of efavirenz over the dosing interval and generally few studies have related unbound concentrations of antiretrovirals to IC exposure. The drug efflux pump, P-glycoprotein (P-gp), has been shown to limit IC concentrations of some protease inhibitors. 4, 11, 12 However, there are relatively few data investigating active transport of the non-nucleoside reverse transcriptase inhibitors (NNRTIs), particularly efavirenz. Although efavirenz is not thought to be a substrate for P-gp, 13 Fellay et al. 14 showed differential immune reconstitution in patients taking efavirenz with allelic variations in MDR1 (the gene encoding P-gp). The authors postulated that subjects with lower cellular P-gp expression, with the TT genotype, might have higher IC efavirenz concentrations giving better suppression of HIV replication.
The aim of this study was to quantify IC concentrations of efavirenz in vivo and to calculate the total IC exposure over the dosing interval (AUC 0-24 ). IC exposure was then related to plasma efavirenz (total and unbound) AUC 0-24 , P-gp expression on the surface of lymphocytes and to the log P of efavirenz.
Materials and methods

Materials
Lymphoprep was purchased from Nycomed Pharma AS (Oslo, Norway). PBS tablets were purchased from Gibco Life Technologies Ltd (Paisley, UK). CellFIX was purchased from Becton Dickinson (Oxford, UK). Anti-IgG2a negative control antibody and goat antimouse IgG2a R-phycoerythrin conjugated secondary antibody were purchased from Serotech (Oxford, UK). UIC2 antibody was obtained from Imunotech (Marseille, France). Amicon Centrifree Filter Systems were purchased from Millipore Corporation (Bedford, MA, USA). HPLC grade acetonitrile, methanol, ethyl acetate n-octanol and n-hexane were purchased from Sigma-Aldrich Company Ltd. (Dorset, UK). Ammonium acetate and potassium carbonate were purchased from Fisher Scientific (Leicestershire, UK). Buffy coats and blank plasma were purchased from the National Blood Transfusion Service (Liverpool, UK). Internal standard (Ro31-9564) was obtained from Roche (Basel, Switzerland). Efavirenz was obtained from BMS DuPont (Wallingford, USA).
Determination of the partition coefficient of efavirenz
The traditional n-octanol-water shake flask method 15, 16 was used to determine the lipophilicity of efavirenz. This was consistent with previous investigations with the protease inhibitors 17 and therefore allowed comparisons between the drugs to be made. This method determines the relative distribution of a given drug into either n-octanol saturated water (lipid bilayer-like) or n-octanol (lipid-like).
Equal volumes of analytical grade n-octanol and distilled water were mixed (24 h) before the phases were allowed to separate (12 h). The top layer (n-octanol) was discarded leaving the n-octanol saturated water. A stock solution of efavirenz was prepared in n-octanol, which was added to equal volumes of n-octanol saturated water to yield final concentrations of either 5 mM (1332 ng/mL) or 10 mM (2663 ng/mL). Samples were mixed on a mechanical shaker (30 min) and left to stand (2 h) to allow separation of the two phases. Three aliquots (of varying volumes) of each phase were collected carefully to avoid contamination. Samples were evaporated to dryness using a rotary evaporator and drug levels quantified using IC methods described below.
The partition coefficient (P) was calculated as a ratio of the concentration of drug residing in the organic phase (n-octanol) divided by the concentration of drug in the aqueous phase (n-octanol saturated water). Log P was calculated as the log 10 (partition coefficient).
Subjects
Ten subjects (6 male, 4 female; 7 Caucasian, 3 Black-African) with a median age of 35 years (range 23-59 years) were enrolled into this study. Routes of HIV infection (number of patients) were heterosexual transmission (n = 5), homosexual transmission (n = 4) and via injecting drug use (n = 1). Each subject provided written informed consent to participate in the study, which was approved by the local ethics committee. All subjects were receiving dual NRTIs plus efavirenz (600 mg once a day) for a median duration of 24 months (range 6-48 months). Concurrent NRTIs (number of patients) were lamivudine (n = 7), zidovudine (n = 6), stavudine (n = 4) and didanosine (n = 1).
Exclusion criteria were: age <18 years, pregnancy or breast feeding, evidence of pre-existing impairment of liver (ALT >5 times upper limit of normal) or renal function (creatinine >300 mmol/L), anaemia (Hb <10.0 g/dL), acute bacterial/viral infection (other than HIV), chronic hepatitis B or hepatitis C, and whether receiving the following or not: cytotoxic chemotherapy, rifampicin, verapamil, macrolide antibiotics or non-steroidal anti-inflammatory drugs within the previous 2 weeks, and a-interferon or IL-2 within the previous 2 months.
To allow laboratory analysis of samples throughout the profile, all patients were switched from evening doses of efavirenz to a morning dose. This was done over a period of 3 days to create minimum alterations in exposure to efavirenz (day 3, 600 mg once a day in the evening; day 2, 200 mg in the morning plus 400 mg in the evening; day 1, 400 mg in the morning dose plus 200 mg in the evening; day 0, 600 mg once a day in the morning-pharmacokinetic sampling day). After the study day evening doses were resumed, using the same 3 day strategy in reverse.
For pharmacokinetic analysis, five blood samples were obtained from each participant over the 24 h dosing period. The first sample was provided immediately prior to their morning dose (0 h, 35 mL) and then four samples of 25 mL at 2, 6, 12 and 24 h post dose. The total blood volume donated by each subject over the study period was therefore 135 mL. Blood samples were collected into lithium heparin tubes.
Isolation of PBMCs
At each time point, blood (5 mL) was centrifuged (700 g, 6 min, 4 C) to yield plasma. Plasma was then stored at -20 C prior to analysis. Plasma and peripheral blood mononuclear cells (PBMCs) were isolated from the remaining blood sample using density gradient centrifugation (700 g, 25 min, 4 C) and cell density was determined using a haemocytometer. Isolated PBMCs were then washed in ice-cold PBS and centrifuged (700 g, 4 min, 4 C) three times to remove extracellular drug before extraction in methanol (1 mL, 60% v/v, 12 h). This initial extraction procedure was incorporated into the assay to ensure adequate removal of cell debris. Prior to methanol extraction, an aliquot of PBMCs (4-7 · 10 6 cells) was removed for determination of P-gp expression. Importantly, the time between blood sampling and methanol extraction was consistently £1 h and all sample processing within this time was carried out under ice-cold conditions to prevent drug loss. These samples were then centrifuged (2772 g; 4 min, 4 C) and the supernatant poured into glass tubes and dried using a rotary evaporator. Samples were stored as dried extracts at -20 C until analysis.
Total and unbound drug separation
Ultrafiltration was used to separate protein bound and unbound drug in plasma. Heat-inactivated plasma (800 mL) was injected into an Amicon Centrifree Filter System and centrifuged (1800 g; 60 min). A temperature of 37 C was maintained during centrifugation to prevent alterations in drug protein binding. The resulting filtrate (220 mL/sample), which contained only the unbound drug, was removed for analysis.
Quantification of efavirenz
Quantification of total, unbound and IC efavirenz was carried out using HPLC with UV detection (HPLC-UV). Internal standard (IS; 20 mL, 10 mg/mL) was added to dried PBMC extracts (reconstituted in 200 mL distilled water), ultrafiltrate samples (200 mL) and plasma standards (200 mL, range 5-1000 ng/mL; note that the matrix did not alter the slope of the standard curve). IS (20 mL, 250 ng/mL) was added to heat inactivated (58 C, 40 min) plasma samples (200 mL) and standards (range 100-8000 ng/mL; 200 mL). Potassium carbonate (100 mL, 1 M) and ethyl acetate/n-hexane (50:50 v/v; 3 mL) were added to each tube and the samples tumbled for 30 min using a rotary mixer. Following centrifugation (3291 g; 6 min), the aqueous layer was frozen using a cryogenic bath, the organic layer transferred into clean glass tubes and evaporated to dryness. Dried extracts were then reconstituted in mobile phase (150 mL), vortexed thoroughly and transferred into autosampler vials ready for injection (100 mL) in the HPLC system. Recovery of efavirenz, after extraction from plasma, using this method is 98%.
Efavirenz and IS were resolved on a (5 mm: 250 · 4.6 mm) Hypurity Elite C 18 column (Thermo Hypersil-Keystone, Runcorn, UK) with a pre-column guard (Si 60 · 5 mm; Merck, New Jersey, USA) with an HPLC system (Kontron Instruments Ltd, Hertfordshire, UK) using the mobile phase (10 mM ammonium acetate buffer/acetonitrile/ methanol; 40/52/8; by vol.) at a flow rate of 1.2 mL/min. Efavirenz and IS eluted at 4.8 and 13.9 min, respectively. The peak areas for efavirenz and IS were quantified using the Chromeleon (Version 6.5) data acquisition system (Dionex Corporation, California, USA). The lower limit of quantification (LLQ) of efavirenz in plasma and ultrafiltrate were taken as the lowest point on the standard curves (100 and 5 ng/mL for the two standard curves). Intra-assay and interassay coefficients of variation at 5 ng/mL were 10.8 and 14.9%, respectively. The quantification if IC efavirenz is dependent on cell number, therefore a minimum number of 20 · 10 6 cells were required from each sample. The laboratory also participates in an external quality assurance programme (KKGT, The Netherlands).
Determination of P-gp expression
The aliquot of PBMCs saved for P-gp analysis was centrifuged (2772 g, 4 min, 4 C) and the cells fixed (CellFIX 1:10, 1 mL, 30 min, 4 C). PBMCs were then centrifuged (700 g, 4 min, 4 C) and the resulting pellet resuspended in PBS to give a cell density of 2 · 10 6 cells/mL. Aliquots of cell suspension (200 mL: 400 000 cells) were then incubated (30 min, 4 C) with primary antibodies; two aliquots with the monoclonal P-gp specific antibody, UIC2, (directed to an extracellular epitope 18 2.4 mg/mL), two with IgG2a isotype control antibody (4.8 mg/ mL) and one left as cells alone. Following primary antibody incubation, cells were washed (1 mL PBS, 4 C) and centrifuged (700 g, 4 min, 4 C) twice before incubation with the R-phycoerythrin-conjugated anti-IgG2a secondary antibody (2.0 mg/mL; 30 min, 4 C). Cells were then washed (1 mL PBS, 4 C) and centrifuged (700 g, 4 min, 4 C) twice, resuspended (CellFIX 1:10, 0.5 mL) and analysed by flow cytometry. It is important to note that validation experiments showed efavirenz did not alter UIC2 binding.
A Coulter Epics XL-MCL flow cytometer was used for sample analysis. Forward and side scatter were detected on a linear scale and fluorescence in the FL-2 channel detected on a logarithmic scale. A clear population of lymphocytes was electronically gated from the total PBMC population, using light scatter properties. For each sample 3000 events were collected within this gate, generating a histogram of FL-2 fluorescence. P-gp expression was analysed by subtracting the histogram generated with the isotype control antibody from that generated with the P-gp-specific antibody, using FCS express software. This was then expressed as % P-gp-positive cells.
Validation experiments
To estimate loss of cell-associated efavirenz during the cell isolation procedure, PBMCs from three single-donor buffy coats were incubated in efavirenz [10 mM (2663 ng/mL), 37 C 5% CO 2 , 18 h], then transferred into drug-free medium and maintained at either 4 C or 37 C for up to 60 min. PBMCs were then washed, incubated in methanol and dried as described above.
Drug loss resulting from efavirenz binding to the filter was quantified using filtered plasma from healthy volunteers, which was spiked with different concentrations of efavirenz. Efavirenz was quantified in these spiked ultrafiltrates before and after a second filtration step. The % recovery was then calculated.
To reduce the risk of HIV transmission in the laboratory, all plasma samples are heat inactivated (58 C, 40 min) prior to storage (-20 C) and analysis. The effect of heat inactivation and a single freeze-thaw cycle on total and unbound plasma concentrations and on the % unbound was investigated using blank plasma spiked with four concentrations of efavirenz (500, 1500, 3000 and 5000 ng/mL).
Patient samples were pooled, split into six aliquots, then filtered and assayed as six independent samples to assess variability associated with both filtration and efavirenz quantification. This was termed inter spin column variation.
Data analysis
IC concentrations (expressed as ng/mL) were calculated using the cell density of the sample and taking 0.4 pL as the volume of a cell (as determined by Gao et al. 19 ). The AUC 0-24 was calculated over the dosing interval for total, unbound and IC exposure, using non-compartmental analysis (Topfit, Version 2.0; Gustav Fischer Verlag, Stuttgart, Germany). Owing to the long half-life of efavirenz, the time points over the dosing interval did not allow for accurate determination of half-life. To account for variability in efavirenz plasma concentrations, IC penetration of efavirenz was calculated as a ratio of IC AUC 0-24 to plasma AUC 0-24. The % unbound efavirenz was calculated as (unbound AUC 0-24 /total AUC 0-24 ) · 100. Interindividual variability (% coefficient of variation; CV) was calculated as (standard deviation/mean) · 100.
Data exhibited no evidence of non-normality (Shapiro-Wilk test). Differences in drug adsorption to filters were tested using an ANOVA test with Bonferroni correction. This test was also used to investigate differences in % unbound efavirenz over the dosing interval.
Relationships between IC efavirenz and protein binding or P-gp expression were investigated using simple linear regression. All statistical analyses was carried out using the Arcus Quickstat Biomedical Software Version 1.1(Ó1997).
Results
The mean -SD percentage recovery of efavirenz following ultrafiltration was 71.0 -3.9, 70.6 -2.3, 74.9 -7.9 and 75.2 -4.3% for plasma concentrations of 500, 1500, 3000 and 5000 ng/mL, respectively. There was no difference in drug adsorption at these concentrations (P > 0.1 for all comparisons). In keeping with other protein binding studies, 10,21,22 unbound concentrations were not corrected for adsorption. Heat inactivation, one freeze-thaw cycle or a combination of heat inactivation followed by a freeze-thaw cycle caused no alteration in total, unbound or % unbound efavirenz. Inter spin column variation was 12.1%. Heat inactivation and a single freeze-thaw cycle caused no alteration in total concentrations, unbound concentrations or % unbound efavirenz at plasma concentrations of 500, 1500, 3000 and 5000 ng/mL (P > 0.05 for all comparisons). Following 60 min of incubation of PBMCs in drug-free medium at 4 C, 96.5 -13.8% efavirenz (mean -SD) remained cell associated. This is compared with 68.8 -6.6% at 37 C (Figure 1 ). The mean -SD (n = 4) partition coefficient (log P) was 2.07 -0.12. Figure 2 illustrates total, unbound and IC efavirenz concentrations over the dosing interval. The median (range) total, unbound and IC efavirenz AUC 0-24 are described in Table 1 . All total, unbound and IC efavirenz concentrations were above the LLQ for the assay. The % unbound efavirenz (calculated for individual time points) in plasma was constant over the full dosing interval (P > 0.05 in all comparisons). No significant relationship was observed between total and unbound efavirenz AUC 0-24 (r 2 = 0.25, P = 0.14). Interindividual variation in total, unbound and IC AUC 0-24 was 46.5, 31.9 and 57.0%, respectively.
A linear relationship was observed between plasma total and IC efavirenz AUC 0-24 (r 2 = 0.59, P = 0.009; Figure 3a ). This was not observed when comparing unbound and IC efavirenz AUC 0-24 (r 2 = 0.13, P = 0.75; Figure 3b ). An inverse linear relationship existed between % unbound efavirenz (calculated from AUCs) and IC efavirenz AUC 0-24 (r 2 = 0.51, P = 0.02; Figure 3c ). There was no association between IC efavirenz AUC 0-24 and P-gp expression (r 2 < 0.01, P = 0.98; Figure 3d ). Similarly, no correlation was observed between P-gp expression and either the IC:total plasma efavirenz AUC 0-24 ratio (r 2 = 0.17, P = 0.24) or the IC:unbound efavirenz AUC 0-24 ratio (r 2 = 0.07, P = 0.47).
Discussion
As the site of action of efavirenz is inside the host cell, investigations of factors which may impact IC concentrations of efavirenz are important. The median IC accumulation ratio was 1.3, indicating that efavirenz concentrations are slightly higher inside (or associated with) the cell compared with in plasma. This is comparable to the accumulation ratio of 0.9 observed by Rotger et al. 3 Indeed, when comparing the values for total and IC AUC 0-24 determined in this study with those predicted using Bayesian calculations 3 the data are similar, despite the methodological differences (HPLC-UV with a LLQ of 5 ng/mL versus LC-MS/MS with LLQ of 0.4 ng/mL).
Here we show that efavirenz is lipophilic (log P of 2.07) and highly plasma protein bound (median % unbound of 0.63%). Studies investigating the IC concentrations of the protease inhibitors have found a general hierarchy of IC accumulation, which is comparable to the hierarchy for lipophilicity and protein binding, 17 suggesting that the physiochemical properties of a drug dictate its IC accumulation. Based on protease inhibitor data it might have been expected that efavirenz would accumulate to a similar extent as nelfinavir (5-fold) or saquinavir (3-fold), 6-8 whereas efavirenz accumulation is actually similar to that reported with ritonavir (accumulation ratio of 1 8 ).
The median % unbound efavirenz observed here in vivo is similar to that stated in the summary of product characteristics. 20 There was no relationship between % unbound efavirenz and serum albumin concentration (data not shown), although all albumin concentrations were within the normal range. It is possible that marked changes in albumin concentration, such as those associated with liver injury, may cause changes in the free fraction. Although there was a trend relating total and unbound plasma AUC 0-24 , this Only 3/10 patients had detectable VL (>50 copies/mL).
Plasma and intracellular efavirenz in vivo 741 JAC antiviral was not statistically significant. The % unbound of some highly protein bound protease inhibitors (lopinavir and amprenavir) have been reported to be concentration dependent in vivo, altering over the dosing interval. 21, 22 Here we present the first data describing the unbound fraction of efavirenz in vivo and suggest that efavirenz binding is not concentration dependent within the range of plasma levels observed over the dosing interval.
Protease inhibitors are weak bases and preferentially bind to a 1 -acid glycoprotein, whereas the NNRTIs are weakly acidic and predominantly bind to albumin 23 Total IC efavirenz concentrations, as measured in this study, are likely to be a composite of the drug that is both bound and unbound to IC proteins. However, characterization of IC binding proteins is needed and any differential binding of protease inhibitors and NNRTIs to IC proteins remains unclear. The ratio of IC efavirenz AUC 0-24 to unbound efavirenz AUC 0-24 was 213, indicating that over 200-fold more drug resides in the cellular compartment compared with the unbound efavirenz in plasma. It is likely that the unbound efavirenz in plasma equilibrates with unbound efavirenz inside the cell, thereby suggesting a high degree of IC binding. As yet there are no available techniques able to distinguish between bound and unbound drug within the cell.
Simple linear regression identified a statistically significant correlation between IC efavirenz AUC 0-24 and total plasma efavirenz AUC 0-24 . After the removal of the outlying individual with a very high total AUC, a trend remained (r 2 = 0.38, P = 0.08). A relationship was also observed in another study, 3 and suggests plasma efavirenz concentrations may be good surrogate markers for cellular efavirenz concentrations. As it is unbound drug that is able to diffuse into cells, it was hypothesized that a stronger relationship would exist between unbound and IC efavirenz concentrations rather than between total plasma and IC. However, no relationship was observed between unbound efavirenz AUC 0-24 and IC efavirenz AUC 0-24 . Furthermore, a positive correlation existed between % bound efavirenz in plasma and IC efavirenz AUC 0-24 , suggesting a link between binding in plasma and binding inside the cell. Although the unbound drug will equilibrate between the plasma and cellular compartments, these data suggest the unbound efavirenz concentrations are unlikely to reflect efavirenz levels inside the cell. This may be particularly evident with efavirenz due to its very high affinity for binding. In light of these findings it is anticipated that the majority of efavirenz inside the cell is bound to cellular constituents, highlighting the need for investigation of IC drug kinetics. Although no data are available describing the IC unbound fraction, the cellular distribution of protease inhibitors was investigated using radiolabelled drugs. 8 These investigations reported an even distribution of the protease inhibitors within the cell, which was not the result of protein sequestration. Such studies are only feasible with radiolabelled isotopes, which are not commercially available for efavirenz. P-gp expressed on the surface of lymphocytes has been linked to lower IC accumulation of protease inhibitors in vitro and in vivo.
11, 24 Fellay et al. 14 reported a genetic association between the C3435T SNP in MDR1 and immune reconstitution following efavirenz therapy. The authors suggested this was due to increased IC efavirenz concentrations with lower expression of P-gp. Although this hypothesis is not readily supported by the present data (since there was no relationship between IC efavirenz AUC 0-24 and P-gp expression), like most studies investigating IC exposure of antiretrovirals the present study was an intensive pharmacokinetic study on a small number of patients. It is possible that the C3435T SNP is associated with immune reconstitution through a P-gp-independent mechanism, such as linkage to another SNP. Interestingly, other studies found no association between C3435T and either plasma 25, 26 or IC efavirenz, 26 perhaps supporting the suggestion of a mechanism independent of P-gp.
A limitation of this study is its small sample size, and much larger studies are needed to address the crucial question of the relationship between IC concentrations of antiretrovirals and clinical response. However, this is difficult with full IC profiles given the amount of blood required at each time point. Rotger et al. which makes a larger study population much more practical. 3 However, there are potential problems when using ratios of single time points. Indeed, consensus statements following a round table discussion of sanctuary sites concluded that single time points may not be adequate to assess drug exposure in sanctuary sites and that the ratio of AUCs (sanctuary site:total plasma) is preferable. 27 However, as we observed, similar findings to those predicted by Rotger et al., 3 such as Bayesian calculations or the use of limited sampling strategy models, may be useful for further mechanistic studies.
Of interest is the complete contrast that is observed when considering the IC pharmacokinetics of the two NNRTIs, efavirenz and nevirapine. We recently reported a low IC accumulation ratio (0.005) of nevirapine, whereas here we observe an IC accumulation ratio of efavirenz that is 250 times higher (1.3), even though similar lipophilicities were observed. 10 It is therefore likely that these drugs have different affinities for active efflux and influx transporters and for binding proteins within the cell.
In summary, this study measured total, unbound and IC efavirenz AUC 0-24 , and the first data describing unbound efavirenz in plasma in vivo are presented. Future studies should aim to (i) develop a method for determining the IC localization of efavirenz, (ii) quantify the unbound efavirenz concentration within the cell and (iii) relate IC efavirenz concentrations to antiviral activity to give some indication of the amount of drug that is required inside the cell in order to inhibit viral replication.
